Revenue Arc research
Revenue Arc B2B Scaling Study 2026
Most work on scaling reads the winners. This study reads 78 companies that failed to scale and 108 that scaled, against the same frame.
Companies read
The two groups
What the failures cost
Both money figures are floors, and they are never added together. One counts cash that was spent and not returned. The other counts value that was only ever a price on paper.
One
What it is
The B2B Scaling Study 2026 is a study of 186 B2B technology companies: 78 that failed to scale and 108 that scaled.
The Study is built from primary records, such as annual reports, filings with regulators, and court and insolvency papers written at the time, rather than from interviews about what people remember.
The register holds 212 companies, being the 186 in the Study and 26 considered and not admitted. Twelve companies moved after they had been coded, ten off the failure side and two off the success side, and none was deleted. Every ruling is recorded and reversible.
Two
Why it was built this way
Most work on scaling reads the winners.
Reading only the winners cannot tell you which of their habits mattered, because the companies that had the same habits and failed are not part of the study.
So this study reads both groups, and scores them against the same frame.
That matters more than the size of the study. A fault tells you something only if it shows up in the companies that failed and not in the ones that succeeded.
Three
What the instrument tests
Four conditions. A company is scaling only while all four hold at the same time. The weakest one decides, and strength on three can never buy back a failure on the fourth.
Durability
It keeps.
The money you already earn keeps coming. Customers won last year are still paying this year, at the same price or better, without being rescued, heavily discounted, or propped up by extra people.
Repeatability
It repeats.
New customers are won by a method the company owns, not by luck or by the relationships of a select group of senior people. It is proved by transfer: the same win, produced by a different seller, across the range of customers the company aims at, at the normal price.
Compounding
It multiplies.
Growth arrives that nobody paid for. Customers already on board buy more each year they stay, work delivered for one customer helps win the next, and each new win costs no more than the one before it.
Absorbable pace
It absorbs.
The company takes on customers, staff and markets no faster than it can carry them. It is read from what breaks first: complaints rising against last year, customers waiting longer to get started, and new joiners taking longer to become productive than they did a year ago.
Four
What it found
The most common pattern in the failure set was mistaking outside endorsement for evidence that the business worked. A funding round, a logo, an analyst's note or a competitor's valuation was treated as proof, when none of them is.
Next most common was installing a method that had worked somewhere else without testing whether it fitted here. Then leadership that could not revise a theory, because their standing rested on having been right before. Then companies that saw the parts of the business but never the system connecting them. Then companies that had been told the bad news for so long that they had stopped hearing it.
Most companies carried more than one. These are patterns the Study coded in the failures from public records, not causes of failure and not measured rates.
Five
Why this study exists
Four studies dominate boardroom conversation about growth: Bain's Founder's Mentality, Startup Genome's Scaleup Report, Jim Collins's Good to Great, and Lee and Kim's 2024 paper in the Strategic Management Journal.
None of them examined the mid-market B2B technology company. Bain's sample sat far above it and Startup Genome's far below. Collins studied large United States public companies between 1965 and 1995. Lee and Kim worked from job postings at mostly early-stage firms.
So the company that makes up most of a mid-market technology portfolio had never been the subject of a study that read scaling failures and scaling successes together. This is that study.
Six
The comparison
The same nine questions put to this study and to the four it sits beside.
The B2B Scaling Study 2026
Revenue Arc, 2026
- Who it studied
- 186 B2B technology companies, across the growth range.
- The mid-market technology company
- Yes, and across every ownership structure it might have.
- What counted as success
- Durable operating scale: value that held, defined before analysis began.
- Studied failure directly
- Yes: 78 companies that failed to scale, reconstructed from primary records.
- Counted the money lost
- Yes: two measures, reported separately, never summed.
- Covers 2020 to 2025
- Mostly, and isolates the cheap-capital vintage as its own pattern.
- Re-tests its own winners
- Yes: a dated durability test that moved two successes to the failure set; a later review kept one there and removed the other from both sets.
- Ends in
- A decision: Scale Readiness Proven, Scale Readiness Conditional, or Scale Readiness Unproven.
- Evidence inspectable
- On validated request: every company and every ruling, including the twelve that were reversed.
The Founder's Mentality
Bain
- Who it studied
- A database of roughly 8,000 global public companies, all sectors and sizes, with interviews with executives and founders.
- The mid-market technology company
- No. Mostly far larger.
- What counted as success
- Sustained growth without stall-out.
- Studied failure directly
- Indirectly: crises inside survivors.
- Counted the money lost
- No.
- Covers 2020 to 2025
- No: fieldwork ended around 2015.
- Re-tests its own winners
- No.
- Ends in
- A mindset.
- Evidence inspectable
- Proprietary.
The Scaleup Report
Startup Genome
- Who it studied
- Tens of thousands of young startups, through its founder survey, pre-scale.
- The mid-market technology company
- No. Mostly far smaller.
- What counted as success
- Reaching a US$50m valuation mark.
- Studied failure directly
- Only as a line on a chart.
- Counted the money lost
- No.
- Covers 2020 to 2025
- Partly, through a valuation lens.
- Re-tests its own winners
- No.
- Ends in
- Benchmarks.
- Evidence inspectable
- Partly; founder self-report.
Good to Great
Jim Collins
- Who it studied
- Large established public companies of the 1965 to 1995 era.
- The mid-market technology company
- No. Fortune-500 scale.
- What counted as success
- Fifteen years of stock-market outperformance.
- Studied failure directly
- No: the comparison firms all survived.
- Counted the money lost
- Stock returns only.
- Covers 2020 to 2025
- No: the data ends in the 1990s.
- Re-tests its own winners
- No: several exemplars later collapsed in print.
- Ends in
- A philosophy.
- Evidence inspectable
- Not reproducible.
Lee and Kim, 2024
Strategic Management Journal
- Who it studied
- Over 38,000 United States startups, mostly early stage, through 6.3 million job postings.
- The mid-market technology company
- No. Pre-scale.
- What counted as success
- The timing of the first managerial and sales hires.
- Studied failure directly
- Only as a statistical outcome.
- Counted the money lost
- No.
- Covers 2020 to 2025
- Partly.
- Re-tests its own winners
- Not applicable.
- Ends in
- A finding.
- Evidence inspectable
- Yes, in principle.
Seven
Five things the four studies do not do
It studied the right population.
Findings drawn from Fortune-500 conglomerates or seed-stage startups reach a mid-market portfolio only by analogy, and an analogy is not evidence about your company. This study needs no such step across. Venture-backed, sponsor-backed, listed and founder-controlled companies all appear on both sides of the line, so no ownership structure is exempt from the findings.
It measured the outcome that pays.
Startup Genome's finishing line is a US$50 million valuation. That is paper, and the correction of 2022 showed how far paper can move without any cash changing hands. Collins's finishing line was fifteen years of share-price outperformance, and several of his eleven companies later failed. This study's finishing line is value that held.
It counted the money, honestly.
Two measures, reported separately and never added together. One counts paper that was never cash. The other counts cash that never came back. Adding them would produce a larger number and a false one, so the study does not add them.
It covers the era every current portfolio is living through.
Most of the failures ended between 2020 and 2025: the cheap-capital surge, the megaround cluster and the correction that followed. Some ended between 2016 and 2019. The cheap-capital years were tested as a rival explanation rather than assumed away.
It ends in a decision, not a philosophy.
Bain ends in a mindset, Collins in a set of virtues, Startup Genome in benchmarks. This study ends in one of three results a board can act on: Scale Readiness Proven, Scale Readiness Conditional, or Scale Readiness Unproven.
Eight
The study re-tests its own winners
In 2001, Good to Great named eleven companies as enduringly great. Circuit City filed for bankruptcy in 2008 and was liquidated in 2009, and Fannie Mae passed into government conservatorship in 2008. Neither verdict was ever withdrawn.
This study re-tested its own success cases as at 18 June 2026. It moved two cases to the failure set, on the record, with the date on the entry; a later review kept one there and removed the other from both sets.
We know of no other study of company growth that has demoted its own success cases.
Re-testing is what makes the success set checkable, rather than fixed at the date it was published.
Nine
The two questions sceptics ask
Only 186 companies?
The number to compare is depth per company, not sample size. Bain's 8,000 companies were screened by database, and the mechanism work rests on interviews with executives and founders. Collins's five-year programme, with twenty-one researchers, analysed eleven companies in depth. This study coded 186 companies, each against the same frame, from graded primary sources.
Where is the famous name on the cover?
A famous name asks you to trust the result. This study shows how it reached the result. Every source is graded, and a claim without primary verification is downgraded rather than promoted. Undisclosed private figures are recorded as ceilings and never guessed. Every company the Study ruled out is recorded with the rule that ruled it out, and so are the twelve rulings reversed after coding. Nothing was deleted to tidy the count. To request the full register, email mark@revenuearc.co.uk. Each request is reviewed.